Nevirapine plus Zidovudine to Prevent Mother-to-Child Transmission of HIV
Authors:
- C HerzmannCHC Herzmann
- H KarcherHKH Karcher
- 4 November 2004
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 351 (19) , 2013-2015
Abstract
The articles by Lallemant et al. and Jourdain et al. (July 15 issue)1,2 highlight a dilemma. Should we impair the health of one patient to help another patient? Of the women receiving nevirapine, 32 percent showed resistance mutations to nonnucleoside reverse-transcriptase inhibitors (NNRTI) at 10 days post partum.2 However, viral rebound may occur 21 days3 after receipt of the drug and result in an even higher rate of resistance mutations to NNRTI. Of the mothers receiving zidovudine monotherapy, 6.3 percent transmitted the human immunodeficiency virus (HIV) to their infants, as compared with 2.8 percent of mothers treated with additional nevirapine.1 Unfortunately, no data are given on resistance mutations in infected babies. Resistance mutations might be present in 46 percent of vertically infected babies after nevirapine prophylaxis.4Keywords
This publication has 9 references indexed in Scilit:
- Intrapartum Exposure to Nevirapine and Subsequent Maternal Responses to Nevirapine-Based Antiretroviral TherapyNew England Journal of Medicine, 2004
- Single-Dose Perinatal Nevirapine plus Standard Zidovudine to Prevent Mother-to-Child Transmission of HIV-1 in ThailandNew England Journal of Medicine, 2004
- Clinical implications of stopping nevirapine‐based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistanceHIV Medicine, 2004
- HIV Drug ResistanceNew England Journal of Medicine, 2004
- Molecular Characterization of Preintegration Latency in Human Immunodeficiency Virus Type 1 InfectionJournal of Virology, 2002
- Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012)AIDS, 2001
- Early Detection of Reverse Transcriptase Activity in Plasma of Neonates Infected With HIV-1: A Comparative Analysis With RNA-Based and DNA-Based Testing Using Polymerase Chain ReactionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- A Trial of Shortened Zidovudine Regimens to Prevent Mother-to-Child Transmission of Human Immunodeficiency Virus Type 1New England Journal of Medicine, 2000
- Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trialThe Lancet, 1999